CancerVax to Webcast Corporate Presentation at Pacific Growth Equities Life Sciences Growth Conference.Business Editors/Health/Medical Writers BIOWIRE2K Pacific Growth Equities Life Sciences Growth Conference CARLSBAD, Calif.--(BUSINESS WIRE)--June 3, 2004 CancerVax Corporation (Nasdaq:CNVX) announced today that President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. David F. Hale will present a corporate overview on Wednesday, June 9, 2004 at 8:30 a.m. Pacific (11:30 a.m. EST EST electroshock therapy. EST abbr. electroshock therapy ) during the Pacific Growth Equities Life Sciences Growth Conference. Mr. Hale's presentation will provide an overview of the Company's pipeline of biological products for the treatment and control of cancer, including Canvaxin(TM), a specific active immunotherapeutic product candidate currently being evaluated in two ongoing Phase 3 clinical trials for the treatment of advanced-stage melanoma. A live recording of CancerVax's presentation will be available at http://ir.cancervax.com. To access the presentation, click on the link entitled "Event Schedule" on the left side of the screen. The webcast will be available for 30 days and then archived. About CancerVax Corporation (www.cancervax.com) CancerVax Corporation is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. The Company's lead product candidate, Canvaxin(TM), is one of a new class of products being developed in the area of specific active immunotherapy active immunotherapy The administration of substances to evoke a protective immune response in the form of specific antibodies. Cf Passive immunotherapy, Vaccine. , also known as therapeutic cancer vaccines Cancer vaccines A treatment that uses the patient's immune system to attack cancer cells. Mentioned in: Pancreatic Cancer, Exocrine . Canvaxin(TM) is currently being studied in two international Phase 3 clinical trials for the treatment of patients with Stage III or Stage IV, or advanced-stage, melanoma. The Company is also finalizing the design of exploratory Phase 2 clinical trials for patients with metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. colon cancer and, potentially, other advanced-stage solid tumors. CancerVax also plans to identify and develop new product candidates based on its proprietary specific active immunotherapy, anti-angiogenesis and T-oligonucleotide, or telomere telomere /telo·mere/ (tel´o-mer) an extremity of a chromosome, which has specific properties, one of which is a polarity that prevents reunion with any fragment after a chromosome has been broken. homolog hom·o·log n. Variant of homologue. oligonucleotide, technology platforms, as well as on its human monoclonal antibody technology. CancerVax's corporate headquarters and research and development facility is located in Carlsbad, California and its biologics manufacturing facility is located in the Los Angeles, California area. CancerVax(R) is a registered trademark of CancerVax Corporation. Canvaxin(TM) is a trademark of CancerVax Corporation. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion